{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:20:08Z","timestamp":1792804808309,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024396","name":"Healthcare Quality Improvement Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024396","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015846","name":"Llywodraeth Cymru","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015846","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012360","name":"Heart of England NHS Foundation Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012360","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300599"],"award-info":[{"award-number":["NIHR300599"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejca.2025.115335","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T02:46:09Z","timestamp":1740969969000},"page":"115335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7470-3014","authenticated-orcid":false,"given":"Joanna","family":"Dodkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5140-8495","authenticated-orcid":false,"given":"Emily","family":"Mayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3278-9491","authenticated-orcid":false,"given":"Marina","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9695-6052","authenticated-orcid":false,"given":"Matthew G.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8429-957X","authenticated-orcid":false,"given":"Jemma","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Nossiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Cowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Tree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"van der Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2025.115335_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"issue":"10437","key":"10.1016\/j.ejca.2025.115335_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115335_bib3","unstructured":"Population estimates for the UK, England, Wales, Scotland, and Northern Ireland: mid-2022; 11.11.24; Available from: \u3008https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2022\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib4","unstructured":"The National Prostate Cancer Audit State of the Nation Report 2023. Available from: \u3008https:\/\/www.npca.org.uk\/content\/uploads\/2024\/02\/REF433_NPCA-SotN-Report_230124_v2.pdf\u3009."},{"issue":"8","key":"10.1016\/j.ejca.2025.115335_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"10024","key":"10.1016\/j.ejca.2025.115335_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"32","key":"10.1016\/j.ejca.2025.115335_bib7","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115335_bib8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115335_bib9","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.115335_bib10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115335_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2025.115335_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ejca.2025.115335_bib13","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2025.115335_bib14","unstructured":"NICE hormone-sensitive metastatic prostate cancer: docetaxel evidence summary [ESUOM50]; 2016 11\/02\/2025]; Available from: \u3008https:\/\/www.nice.org.uk\/advice\/esuom50\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib15","unstructured":"NICE Enzalutamide for treating hormone-sensitive metastatic prostate cancer technology appraisal guidance Reference number:TA712; 2021 11\/02\/2025]; Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta712\/chapter\/1-Recommendations?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib16","unstructured":"NICE Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer technology appraisal guidance Reference number:TA741; 2021 11\/02\/2025]; Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ta741\/chapter\/1-Recommendations?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib17","unstructured":"NHS England Interim clinical commissioning policy proposition: Abiraterone acetate and prednisolone for high-risk, hormone sensitive metastatic prostate cancer (adults) [2424]; 2024 11\/02\/2025]; Available from: \u3008https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2024\/12\/2424-Abiraterone-acetate-metastatic-prostate-cancer-interim-clinical-commissioning-policy-proposition-post-pan.pdf?utm_source=chatgpt.com\u3009."},{"issue":"12","key":"10.1016\/j.ejca.2025.115335_bib18","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.ejca.2025.115335_bib19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115335_bib20","article-title":"Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \"real world\"? A systematic review","author":"Dodkins","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2025.115335_bib21","doi-asserted-by":"crossref","unstructured":"Rulach RJ, et al. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. BJU Int. Vol. 121(no. 2). p. 268\u201374.","DOI":"10.1111\/bju.14025"},{"issue":"23","key":"10.1016\/j.ejca.2025.115335_bib22","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1002\/cam4.4372","article-title":"Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration","volume":"10","author":"Freedl","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.ejca.2025.115335_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1080\/0284186X.2020.1847321","article-title":"Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden","volume":"60","author":"Fallara","year":"2021","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2025.115335_bib24","unstructured":"Azad AA, et al. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Int Med J. Vol. 12. p. 12."},{"issue":"3","key":"10.1016\/j.ejca.2025.115335_bib25","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/0284186X.2021.2023215","article-title":"Time on treatment with abiraterone in men with de novo metastatic castration sensitive prostate cancer: a drug utilization study","volume":"61","author":"Gedeborg","year":"2022","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2025.115335_bib26","unstructured":"The National Prostate Cancer Audit 09\/01\/2024]; Available from: \u3008https:\/\/www.npca.org.uk\/\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib27","unstructured":"World Health Organisation. International statistical classification of diseases and related health problems (11th revision); 26\/10\/2022]; Available from: \u3008https:\/\/www.who.int\/standards\/classifications\/classification-of-diseases\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib28","unstructured":"National Health Service. Hospital Episode Statistics; 26\/10\/2022]; Available from: \u3008https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics\u3009."},{"key":"10.1016\/j.ejca.2025.115335_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.canep.2018.11.003","article-title":"Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions","volume":"58","author":"Parry","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115335_bib31","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/bjs.6930","article-title":"Identifying co-morbidity in surgical patients using administrative data with the Royal College of Surgeons Charlson Score","volume":"97","author":"Armitage","year":"2010","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.ejca.2025.115335_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035395","article-title":"Construction of the secondary care administrative records frailty (SCARF) index and validation on older women with operable invasive breast cancer in England and Wales: a cohort study","volume":"10","author":"Jauhari","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejca.2025.115335_bib34","unstructured":"Noble M, The English indices of deprivation 2007; 2008."},{"key":"10.1016\/j.ejca.2025.115335_bib35","unstructured":"ONS. 2011 rural\/urban classification. Available from: \u3008https:\/\/www.ons.gov.uk\/methodology\/geography\/geographicalproducts\/ruralurbanclassifications\/2011ruralurbanclassification\u3009."},{"issue":"8","key":"10.1016\/j.ejca.2025.115335_bib36","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.clon.2016.02.004","article-title":"Organisation of prostate cancer services in the English national health service","volume":"28","author":"Aggarwal","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"1","key":"10.1016\/j.ejca.2025.115335_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12913-017-2341-x","article-title":"The hub-and-spoke organization design: an avenue for serving patients well","volume":"17","author":"Elrod","year":"2017","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.115335_bib38","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"19","key":"10.1016\/j.ejca.2025.115335_bib39","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.280.19.1690","article-title":"What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes","volume":"280","author":"Zhang","year":"1998","journal-title":"Jama"},{"issue":"8","key":"10.1016\/j.ejca.2025.115335_bib40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/sim.1970","article-title":"Funnel plots for comparing institutional performance","volume":"24","author":"Spiegelhalter","year":"2005","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2025.115335_bib41","unstructured":"National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management; 2019 26\/10\/2022]; Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ng131\u3009."},{"issue":"1","key":"10.1016\/j.ejca.2025.115335_bib42","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1748-5908-9-37","article-title":"Examining and addressing evidence-practice gaps in cancer care: a systematic review","volume":"9","author":"Bryant","year":"2014","journal-title":"Implement Sci"},{"issue":"8","key":"10.1016\/j.ejca.2025.115335_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082313","article-title":"Unequal access to newly registered cancer drugs leads to potential loss of life-years in Europe","volume":"12","author":"Uyl-de Groot","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115335_bib44","unstructured":"How health care is funded: the king's fund; 14.10.2024]; Available from: \u3008https:\/\/www.kingsfund.org.uk\/insight-and-analysis\/long-reads\/how-health-care-is-funded#how-is-the-nhs-in-england-currently-funded?\u3009."},{"issue":"6","key":"10.1016\/j.ejca.2025.115335_bib45","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.clgc.2022.06.017","article-title":"Treatment intensification patterns and utilization in patients with metastatic castration-sensitive prostate cancer","volume":"20","author":"Heath","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115335_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkab082","article-title":"Real-world use of androgen-deprivation therapy: intensification among older Canadian men with de novo metastatic prostate cancer","volume":"5","author":"Wallis","year":"2021","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.ejca.2025.115335_bib47","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer\u2014metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115335_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","article-title":"Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: a meta-analysis","volume":"173","author":"Ciccarese","year":"2022","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2025.115335_bib49","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/JU.0000000000003370","article-title":"The role of physician specialty in the underutilization of standard-of-care treatment intensification in patients with metastatic castration-sensitive prostate cancer","volume":"209","author":"Swami","year":"2023","journal-title":"J Urol"},{"issue":"4_suppl","key":"10.1016\/j.ejca.2025.115335_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.224","article-title":"Barriers and facilitators to first-line (1L) treatment intensification (TI) in metastatic castration-sensitive prostate cancer (mCSPC): the IMPLEMENT study","volume":"42","author":"Loeb","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2025.115335_bib51","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ejca.2025.115335_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.627083","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"11","author":"Sung","year":"2021","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2025.115335_bib53","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2025.115335_bib54","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1016\/j.annonc.2020.08.938","article-title":"679P treatment patterns of metastatic castration-sensitive prostate cancer (mCSPC): a real-world evidence study","volume":"31","author":"Tagawa","year":"2020","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.ejca.2025.115335_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13194951","article-title":"Treatment pattern and outcomes with systemic therapy in men with metastatic prostate cancer in the real-world patients in the United States","volume":"13","author":"Swami","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.ejca.2025.115335_bib56","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/DCR.0b013e3181ff43d6","article-title":"Older patients and adjuvant therapy for colorectal cancer: surgeon knowledge, opinions, and practice","volume":"54","author":"Jorgensen","year":"2011","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ejca.2025.115335_bib57","unstructured":"National Cancer Institute. NCI comorbidity index overview. Available from: \u3008https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity.html\u3009."},{"issue":"4","key":"10.1016\/j.ejca.2025.115335_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040875","article-title":"The value of real-world data in understanding prostate cancer risk and improving clinical care: examples from Swedish registries","volume":"13","author":"Beckmann","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2025.115335_bib59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41746-020-0277-8","article-title":"Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations","volume":"3","author":"Averitt","year":"2020","journal-title":"NPJ Digit Med"},{"issue":"7","key":"10.1016\/j.ejca.2025.115335_bib60","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/jamaoncol.2023.0998","article-title":"Association of second-generation antiandrogens with cognitive and functional toxic effects in randomized clinical trials: a systematic review and meta-analysis","volume":"9","author":"Nowakowska","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115335_bib61","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/cts.13451","article-title":"Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: a systematic review and network meta-analysis","volume":"16","author":"Huang","year":"2023","journal-title":"Clin Transl Sci"},{"issue":"8","key":"10.1016\/j.ejca.2025.115335_bib62","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.21.00941","article-title":"Health-related quality of life in metastatic, hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international, randomized phase III Trial led by ANZUP","volume":"40","author":"Stockler","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2025.115335_bib63","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"issue":"43","key":"10.1016\/j.ejca.2025.115335_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390396","article-title":"Management of prostate cancer in older adults","author":"Graham","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.ejca.2025.115335_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071674","article-title":"Organisation and delivery of supportive services for patients with prostate cancer in the National Health Service in England and Wales: a national cross-sectional hospital survey and latent class analysis","volume":"13","author":"Dodkins","year":"2023","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.ejca.2025.115335_bib67","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/iju.14256","article-title":"Geriatric 8 screening of frailty in patients with prostate cancer","volume":"27","author":"Momota","year":"2020","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.ejca.2025.115335_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.critrevonc.2006.04.003","article-title":"The abbreviated comprehensive geriatric assessment (aCGA) for use in the older cancer patient as a prescreen: scoring and interpretation","volume":"59","author":"Overcash","year":"2006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115335_bib69","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/ijc.31272","article-title":"Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study","volume":"142","author":"Tomic","year":"2018","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.ejca.2025.115335_bib70","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1002\/cam4.4372","article-title":"Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration","volume":"10","author":"Freedland","year":"2021","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.ejca.2025.115335_bib71","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1002\/cam4.2092","article-title":"Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: a SEER-Medicare investigation","volume":"8","author":"Beebe-Dimmer","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2025.115335_bib72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.amjsurg.2023.12.023","article-title":"Inefficiencies of care in hub and spoke healthcare systems: a multi-state cohort study","volume":"229","author":"Brooks","year":"2024","journal-title":"Am J Surg"},{"issue":"1","key":"10.1016\/j.ejca.2025.115335_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-2026-y","article-title":"A systematic review of geographical variation in access to chemotherapy","volume":"16","author":"Chamberlain","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.115335_bib75","doi-asserted-by":"crossref","first-page":"d1849","DOI":"10.1136\/bmj.d1849","article-title":"Reducing unwarranted variations in healthcare in the English NHS","volume":"342","author":"Mays","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.ejca.2025.115335_bib76","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1016\/S1470-2045(20)30558-1","article-title":"Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit","volume":"22","author":"Aggarwal","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001169?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925001169?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:45:36Z","timestamp":1760640336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925001169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":72,"alternative-id":["S0959804925001169"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115335","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115335"}}